VIVUS (VVUS) Shares Down 5.2%
Shares of VIVUS, Inc. (NASDAQ:VVUS) fell 5.2% during trading on Thursday . The company traded as low as $0.53 and last traded at $0.55. 725,547 shares traded hands during mid-day trading, an increase of 0% from the average session volume of 722,737 shares. The stock had previously closed at $0.58.
Separately, ValuEngine downgraded shares of VIVUS from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.
The company has a market cap of $58.27, a PE ratio of 1.62 and a beta of 0.77. The company has a quick ratio of 7.09, a current ratio of 7.47 and a debt-to-equity ratio of 643.86.
VIVUS (NASDAQ:VVUS) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.07. The business had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.09) earnings per share. equities research analysts expect that VIVUS, Inc. will post -0.32 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. IHT Wealth Management LLC grew its position in VIVUS by 653.3% during the second quarter. IHT Wealth Management LLC now owns 1,130 shares of the biopharmaceutical company’s stock valued at $1,100,000 after purchasing an additional 980 shares in the last quarter. Bank of New York Mellon Corp grew its position in VIVUS by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 114,564 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 7,722 shares in the last quarter. Northern Trust Corp grew its position in VIVUS by 16.8% during the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 39,473 shares in the last quarter. Russell Investments Group Ltd. grew its position in VIVUS by 84.8% during the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 68,200 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new position in VIVUS during the second quarter valued at approximately $100,000. 31.35% of the stock is currently owned by institutional investors and hedge funds.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.